Novartis: seeks to broaden indications for Lucentis

(CercleFinance.com) - Novartis plans to broaden the indications for its Lucentis ophthalmic drug, extending it to retinopathy of prematurity (ROP), a rare disease in prematurely born infants that often leads to blindness.


Based on a favourable benefit-risk profile, Novartis plans to file for the new indication for Lucentis, the company said this weekend.

Separetely, Novartis unveiled a new analysis of a Phase III trial on brolucizumab, reinforcing superior reduction of retinal fluid, a key marker of disease activity in in neovascular age-related macular degeneration (nAMD).

Last Friday Novartis received positive CHMP opinion for Gilenya for the treatment of children and adolescents with multiple scelrosis, as well as a positive CHMP opinion for Luxturna to treat children and adults with rare inherited retinal disease.

Its Sandoz unit also received positive CHMP opinion for a biosimilar version of Amgen's pegfilgrastim, a drug that stimulates white blood cell levels.

Copyright (c) 2018 CercleFinance.com. All rights reserved.